Fusion Between TMPRSS2 and ETS Family Members (ERG, ETV1, ETV4) in Prostate Cancers from Northern China

Wang, Jianjiang; Liu, Yue-Xin; Wang, Wei; Yan, Wei; Zheng, Yiting; Qiao, Lu-Dong; Liú, Dan; Chen, Shan

doi:10.7314/apjcp.2012.13.10.4935

Cited by 11 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So in Sun study, the criteria 'one yellow/one green (or one red) represented abnormal signal patterns indicative of partial deletion' may include cases which were not fusion positive (Sun et al, 2010). Using FISH technique, Wang and Sun identified TMPRSS2:ERG fusion rate of prostate cancer patients from northern and southern China was 46% and 90%, respectively (Sun et al, 2010;Wang et al, 2012). Ren used RT-PCR to detect TMPRSS2:ERG 10 out of 54 (18.5%) cases of prostate adenocarcinoma from eastern China (Ren et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…In present study, we found eastern Chinese prostate cancer patients had a lower incidence of TMPRSS2:ERG, TMPRSS2:ETV1 and TMPRSS2:ETV4 fusion similar to Japanese and Korean, TMPRSS2:ERG incidence is 14.3% (13/91) (95% confidence interval, 7.1%-21.5%) by biopsy specimens or 11.1% (2/18) (95% confidence interval, 0%-25.6) by radical prostatectomy samples and TMPRSS2:ETV1 and TMPRSS2:ETV4 were found in none of the cases. However, the frequency of gene fusion varies among different studies of China, and the reasons maybe complex, probably owing to the sensitivity of the technique used, the number of samples included in the study, the criteria be used to determined a positive signal and the patients from different areas (northern, southern, eastern and western) of China (Dai et al, 2008;Mao et al, 2010;Sun et al, 2010;Xiang et al, 2011;Ren et al, 2012;Wang et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…Six investigations studied Chinese cases, but the outcomes of which were quite dissimilar. The lowest incidence of TMPRSS2:ERG is 7.5%, while the highest is 90% (Dai et al, 2008;Mao et al, 2010;Sun et al, 2010;Xiang et al, 2011;Ren et al, 2012;Wang et al, 2012). Considering the prostate cancer prevalence and aggressiveness, as well as genomic alterations, vary in different ethnic origin and geographic locations (Grönberg et al, 2003;Sim et al, 2005), it is necessary to figure out the prevalence of fusion between TMPRSS2 and ETS family members in prostate cancers patients from eastern China and to explore differences in fusion rates in Different areas of China, other parts of Asia, Europe, and USA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

TMPRSS2:ETS Fusions and Clinicopathologic Characteristics of Prostate Cancer Patients from Eastern China

Dong

Xiao²,

Lü³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

TMPRSS2:ERG gene fusions in prostate cancer have a dominant prevalence of approximately 50.0%, but infomration is limited on differences among ethnic and geographical groups. Some studies focusing on Japanese and Korean patients reported a lower incidence. Investigations concerning Chinese revealed controversial results. We evaluated TMPRSS2:ERG, TMPRSS2:ETV1 and TMPRSS2:ETV4 fusions in more than 100 Eastern Chinese prostate cancer patients. Paraffin blocks of needle biopsy and radical prostatectomy were collected from 91 and 18 patients respectively. All patients' clinicopathologic factors were gathered. TMPRSS2:ERG, TMPRSS2:ETV1 and TMPRSS2:ETV4 fusions were tested by multi-probe fluorescence in situ hybridization (FISH) assay. TMPRSS2:ERG fusions was present in 14.3% biopsy specimens and 11.1% radical prostatectomy patients. Neither TMPRSS2:ETV1 nor TMPRSS2:ETV4 fusion was found in any case. Altogether, 13 (86.7%) TMPRSS2:ERG fusion positive cases possessed deletion pattern and 7 (46.6%) and insertion pattern. Some 5 cases had both deletion and insertion patterns. While 38.5% (5/13) patients with deletion pattern had distant metastasis, except for one metastatic case harboring both deletion and insertion, there were no patients with insertion pattern accompanied with metastasis. There were no differences between fusion positive and negative cases in the distribution of age, PSA, Gleason score and TNM stage. Eastern Chinese prostate cancer patients have a significantly low incidence of TMPRSS2:ERG fusion. They also lack TMPRSS2:ETV1 and TMPRSS2:ETV4 fusion. There are more deletion pattern than insertion pattern in TMPRSS2:ERG positive cases. Fusion positive and negative patients have no clinicopathologic factor differences.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

TMPRSS2:ETS Fusions and Clinicopathologic Characteristics of Prostate Cancer Patients from Eastern China

Dong

Xiao²,

Lü³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The incidence of prostate cancer is associated with age, race, diet, environmental pollution and other factors, including a higher rate of gene fusions of ERG, ETV1, ETV4 and ETV5 with other genes (TMPRSS2, SLC45A3, C15orf21, CANT1, EST14, FOXP1, HERVK17, FLJ35294, HERV-K, ACSL3, NDRG1, DDX5, HNRPA2B1, KLK2) (41). It is now well established that PEA3 transcription factors are involved in prostate tumors and Ewing's sarcoma, as well as in other tumors, as a result of chromosomal translocations with ETV4 (8).…”

Section: Discussionmentioning

confidence: 99%

Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue

et al. 2015

View full text Add to dashboard Cite

Abstract. Prostate cancer is the most frequent urological tumor, and the second most common cancer diagnosed in men. Incidence and mortality are variable and appear to depend on behavioral factors and genetic predisposition. The prostate-derived E-twenty-six factor (PDEF) and E-twenty-six variant 4 (ETV4) transcription factors, and the thymidine phosphorylase (TP) and uridine phosphorylase-1 (UP-1) enzymes, are reported to be components of the pathways leading to tumorigenesis and/or metastasis in a number of tumors. The present study aimed to analyze the mRNA expression levels of these proteins in prostatic cancerous and benign tissue, and their association with clinical and pathological variables. Using quantitative reverse transcription polymerase chain reaction, the mRNA expression levels of PDEF, ETV4, TP and UP-1 were studied in 52 tissue samples (31 of benign prostatic hyperplasia and 21 of prostate adenocarcinomas) obtained from patients treated by transurethral resection of the prostate or by radical prostatectomy. Relative expression was assessed using the ∆-CT method. Data was analyzed using Spearman's tests for correlation. P<0.05 was considered to indicate a statistically significant difference. The results revealed that PDEF, ETV4, UP-1 and TP were expressed in 85.7, 90.5, 95.2 and 100% of the prostate cancer samples, and in 90.3, 96.8, 90.3 and 96.8% of the benign samples, respectively. PDEF and ETV4 exhibited a significantly higher relative expression level in the tumor samples compared with their benign counterparts. The relative expression of TP and UP-1 did not differ significantly between benign and cancerous prostate tissues. The relative expression of TP was moderately and significantly correlated with the expression of ETV4 in the benign tissues. The relative expression of UP-1 was significantly lower in T3 compared with T1 and T2 cancers. These findings indicate that PDEF, ETV4, TP and UP-1 are typically expressed in benign and malignant prostatic tissues. Further studies are necessary to define the role of these proteins as therapeutic targets in prostate cancer.

show abstract

“…The ETS gene fusion rate is highest in the United States (42-60%) and lowest in Asia (21% in Korea and 28% in Japan) (ref. 24,25 ). Mosquera et al 26 examined 100 prostate biopsy specimens from United States patients and reported that non-Caucasian patients were less likely to have a positive TMPRSS2-ERG fusion status than Caucasion patients.…”

Section: Incidence Of Prostate Cancer and Tmprss2-ergmentioning

confidence: 99%

TMPRSS2-ERG gene fusion in prostate cancer

Burdova

Bouchal²,

Tavandzis³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

aBackground. The TMPRSS2-ERG gene fusion is one of the most widely spread chromosomal rearrangements in carcinomas. Since its discovery, a number of studies have examined its diagnostic, prognostic and therapeutic implications for prostate cancer where suitable biomarkers are still lacking. The publication data are inconsistent. The aim of this review was to critically evaluate the current clinical impact of this gene fusion. Methods. The PubMed online database was used to search relevant reviews and original articles. Results. Although the TMPRSS2-ERG gene fusion appears to be a suitable diagnostic biomarker, the prognostic implications of this gene fusion are still unclear. Several new strategies for therapeutically targeting ETS fusions and their modulators have been identified and are currently being investigated. Conclusion. Due to the heterogeneity of prostate cancer, the combination of several biomarkers is necessary to accurately assess the presence of prostate cancer, predict its potential clinical outcome and decide on appropriate therapy (e.g. PARP inhibitors).

show abstract

Fusion Between TMPRSS2 and ETS Family Members (ERG, ETV1, ETV4) in Prostate Cancers from Northern China

Cited by 11 publications

References 8 publications

TMPRSS2:ETS Fusions and Clinicopathologic Characteristics of Prostate Cancer Patients from Eastern China

TMPRSS2:ETS Fusions and Clinicopathologic Characteristics of Prostate Cancer Patients from Eastern China

Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue

TMPRSS2-ERG gene fusion in prostate cancer

Contact Info

Product

Resources

About